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Platelet hyperserotonemia in a subset of Autism Spectrum Disorder (ASD) probands,
efficacy of selective serotonin reuptake inhibitors (SSRIs) in reducing behavioral deficits
and gender-bias in normal serotonin (5-hydroxy tryptamine or 5-HT) synthesis suggest
disruption in stringent regulation of serotonin metabolism in ASD. Therefore, we
investigated the changes in 5-HT and 5-hydroxy indole acetic acid (5-HIAA) in ASD
probands to assess its effect on the behavior of male and female probands. ASD cases
(n = 215) were examined using childhood autism rating scale (CARS). Platelet 5-HT (104
cases and 26 controls) and platelet/plasma 5-HIAA (73 cases and 17 controls) were
estimated using high performance liquid chromatography coupled with electrochemical
detector (HPLC-ECD). In male probands, we observed increase in platelet 5-HT content
in association with increase in the score for adaptive responses and increase in platelet
5-HIAA levels with concomitant decline in the score for intellectual response. Age
did not influence the neurochemical parameters, but imitation, listening responses
and nonverbal communication scores decreased with age. Conversely in female
probands, plasma 5-HIAA level significantly attenuated with age, when platelet 5-HT
content remained unchanged. Interestingly, platelet/plasma 5-HT and plasma 5-HIAA
were higher in female controls. Female probands displayed severe autism-associated
behaviors. Overall results indicate gender-bias in 5-HT and 5-HIAA regulation, which
probably increases the threshold level of ASD phenotypes in the females, thereby
affecting ASD prevalence in a sex-specific manner.
Keywords: gender, behavior, autism spectrum disorder, 5-HT, 5-HIAA
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that serotonergic system has a physiological role in autism since
behavioral responses are mediated through the maintenance of
5-HT and 5-HIAA levels at the synaptic terminals (Duhault
and Boulanger, 1977; Raleigh et al., 1984). Accumulating
evidences including the gender-specific effect of 5-HT level and
function suggest that 5-HT, 5-HIAA, and the severity of ASD
symptoms are regulated differentially in males and females.
Therefore, we have investigated the correlation between these
biochemical parameters and various ASD-specific behavioral
alterations, to elucidate the 5-HT mediated complicities in the
behavioral phenotype and to analyze the effect of gender on the
phenotypic expression.

INTRODUCTION
Way back in 1961 Schain and Freedman suggested
association of ASD with functionally disrupted serotonin
(5-hydroxytryptamine, 5-HT) system, while observing elevated
whole blood 5-HT level in affected individuals. Few subsequent
studies supported this finding and revealed that the trait is
familial (Gabriele et al., 2014). Furthermore, Anderson et al.
demonstrated that the increased level of whole blood 5-HT was
mainly due to its elevation in the platelets, while maintaining the
plasma level in the normal range in ASD probands (Anderson
et al., 1987). With similar observations from various groups,
platelet hyperserotonemia have become one of the best identified
endophenotypes of ASD (Anderson et al., 1990; Hranilovic et al.,
2008). Possible contributing factors for platelet hyperserotonemic
condition and dysfunction could be increased 5-HT synthesis,
decreased degradation of 5-HT and defects in 5-HT signaling
mechanisms that involve transporter and receptor functions
(Hranilovic et al., 2008; Veenstra-VanderWeele et al., 2012).
ASD-associated platelet hyperserotonemia has been a major
development that linked ASD with serotonergic dysfunction.
Efficacy of selective serotonin reuptake inhibitors (SSRIs) in
clinically relieving 5-HT-related behavioral symptoms such as
mood, obsession and social relatedness in autistic individuals
has given more support to this concept (Buchsbaum et al., 2001;
Hollander et al., 2005).
Apart from neurotransmitter function, 5-HT plays a vital
role as neurotrophic factor, facilitating neurodevelopment and
neurogenesis (Moiseiwitsch and Lauder, 1995). Serotonergic
neurons are the earliest formed neurons during mammalian
embryogenesis (Shemer et al., 1991) suggesting its neurotrophic
function apart from being a neurotransmitter. Developmental
defects in metabolic and signaling pathways of the serotonergic
system cause disruption of the brain circuitry leading to
neurodevelopmental problems, the ultimate manifestation of
which usually reflects in behavioral phenotypes. Platelet 5-HT
transporter (SERT) has been extensively studied in ASD as it is a
key regulator of 5-HT homeostasis in the periphery and the brain
(Lesch et al., 1993). Reports on familial nature of the trait (Cook
et al., 1993) and animal models of hyperserotonemia mimicking
the morphological and behavioral attributes reminiscent of ASD,
suggest that systemic elevation of 5-HT levels in ASD has a
genetic basis (Whitaker-Azmitia, 2005).
The level of 5-HT metabolite, 5-hydroxyindole acetic acid
(5-HIAA) is a possible indicator of 5-HT function. Its level is
altered in the cerebrospinal fluid (CSF) as well as in the urine of
ASD children, perhaps a compensatory mechanism to maintain
the 5-HT level (De Grandis et al., 2010; Adamsen et al., 2014).
In general, the 5-HIAA level is higher in infants than in the
adults (Hedner et al., 1986) and age dependent alterations impact
the complexity behind the disorder. This information is helpful
to categorize the subjects based on age for better therapeutic
responses. As stated in some studies, 5-HT and 5-HIAA
parameters show good correlation with behavioral perturbations
(Doudet et al., 1995; Higley et al., 1996) and follow familial mode.
These reports strengthen the genetic complexity underlying the
disorder (Leboyer et al., 1999). Pharmacological findings indicate
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MATERIALS AND METHODS
Selection of Study Participants
Participants of the study were recruited through the Out
Patient’s Department of Manovikas Kendra. ASD diagnosis
was done as per the criteria outlined in the Diagnostic and
Statistical Manual of Mental Disorders (DSM V) (American
Psychiatric Association, 2013). Assessment of ASD cases was
performed using Childhood Autism Rating Scale (CARS), a 15item behavioral rating scale based on observations of various
behaviors that categorized ASD patients into mild-moderate
and severe cases (Schopler et al., 1980). Scores between 30.0
and 36.5 and between 37.0 and 60.0 are classified as mild to
moderate and severe cases, respectively. CARS was assigned
for 215 ASD cases (mean age ± SEM: 5.90 ± 0.24) for this
study. Study protocol was approved by the Human Ethical
Committee of Manovikas Kendra (28042011), which followed
the guidelines of Indian Council of Medical Research, Govt.
of India. All procedures for the recruitment were performed
in accordance with the guidelines and regulations of the
committee. Cases and controls were chosen from the same
native Bengali speaking population from West Bengal. Detailed
family and clinical backgrounds were collected for both the
groups. Controls were typically developing children without
any known developmental or neurological disorders. After
obtaining informed written consent from both cases and
controls or their care-givers for voluntary participation and
involvement in the study, peripheral blood was collected from the
participants. Exclusion criteria for ASD included cases with gross
chromosomal abnormalities, and known neurological and/or
developmental disorders. Drug naïve candidates were used for
unbiased estimation of the neurochemicals (5-HT and 5-HIAA).
Age-matched control subjects were selected for the biochemical
analyses and for various other correlation studies involving
age as a variable.
Total number of control subjects enrolled for this study for
platelet 5-HT analysis is 26 (1 to 11.5 years, mean age ± SEM:
5.60 ± 0.61), male controls is 15 (1 to 11.5 years, mean
age ± SEM: 5.13 ± 0.82) and female controls is 11 (3 to 11 years,
mean age ± SEM: 6.23 ± 0.91). The 5-HT analysis was performed
only for 104 ASD cases (2 to 25 years, mean age ± SEM:
5.69 ± 0.37), of which 87 were male cases (2 to 25 years, mean
age ± SEM: 5.71 ± 0.42) and 17 were female cases (2 to 15 years,
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mean age ± SEM: 5.59 ± 0.83). Platelet and plasma 5-HIAA
were analyzed for 17 controls (1 to 10 years, mean age ± SEM:
5.47 ± 0.66) and the number of male (1 to 10 years, mean
age ± SEM: 5.35 ± 0.93) and female controls was 10 and 7 (3 to
10 years, mean age ± SEM: 5.64 ± 0.99), respectively. ASD cases
used for analysis include, 73 cases in total (2 to 25 years, mean
age ± SEM: 5.56 ± 0.48), 59 male cases (2 to 25 years, mean
age ± SEM: 5.58 ± 0.55) and 14 female cases (2 to 15 years, mean
age ± SEM: 5.50 ± 0.92).

Statistical Analysis
Platelet 5-HT, platelet and plasma 5-HIAA levels and CARS
score were analyzed using SigmaPlot. The total data set was
checked for normality in distribution for each quantifying
variables of each group using the Kolmogorov–Smirnov statistic
methods. If the normality test fails, then comparison of the
differences between two groups was done by Mann-Whitney
(M-W) U statistics. Tests of correlations between pairs of
parameters were done using Spearman’s rank test. All the box plot
diagrams and scattered plot diagrams were done using SigmaPlot.
Power analysis was performed using online freely available
power calculator (https://www.stat.ubc.ca/∼rollin/stats/ssize/).
For Mann Whitney test (with α = 0.05, power = 0.80, effect
size = 0.8), the total desired sample size was calculated to be 54
using the G∗ Power Version 3.1.2 (Faul et al., 2008).

Measurement of Platelet 5-HT, Platelet
and Plasma 5-HIAA
Freshly drawn blood was centrifuged at 400 × g for 15 min at
4◦ C to separate RBCs, white blood cells (WBCs) and plasma.
The upper plasma and platelet rich plasma (PRP) portions were
collected separately. PRP was centrifuged at 1000 × g for 5 min at
4◦ C to collect the platelets as pellet, which was serially washed by
resuspending in 1 ml of acid-citrate dextrose, PBS and PBS with
glucose. Between each wash, the cells were recovered by spinning
at 1000 × g for 5 min at 4◦ C. Finally, it was resuspended in
200 µl PBS containing glucose. From this suspension, 5 µl was
diluted 100 times in platelet diluting buffer and 10 µl of this
diluted suspension was mixed with an equal volume of trypan
blue for counting the platelets in hemocytometer. The remaining
platelet suspension was deproteinized by mixing with an equal
volume of 0.4 M perchloric acid, sonicated at 50 Hz for 30 s,
incubated on ice for 20 min and then centrifuged at 15,000 × g for
15 min at 4◦ C to collect clear supernatant. Similarly, the plasma
was also processed by centrifugation at 1000 × g for 5 min at
4◦ C and clear supernatant was collected. It was deproteinized
by adding equal volume of 0.4 M perchloric acid, incubated
on ice for 20 min and then centrifuged at 15,000 × g for
15 min at 4◦ C to collect clear supernatant. The supernate (10 µl)
from both plasma and platelets were injected separately into
HPLC-ECD (Bioanalytical Systems, Lafayette, United States) for
neurotransmitter analysis (Muralikrishnan and Mohanakumar,
1998; Chakraborti et al., 2016). Here the analytes were separated
based on their hydrophobicity using a non-polar stationary
phase (C18 reverse phase column) and a polar mobile phase.
The flow rate was kept at 0.7 ml/min and the electrochemical
detection using glassy carbon electrode was performed at 740 mV,
for quantification of 5-HT and 5-HIAA with reference to the
retention of known standards under same conditions. 5-HT
content was determined for 104 cases (mean age ± SEM:
5.69 ± 0.37) and 26 controls (mean age ± SEM: 5.60 ± 0.61)
and platelet and plasma 5-HIAA levels were determined for 73
cases (mean age ± SEM: 5.56 ± 0.48) and 17 controls (mean
age ± SEM: 5.47 ± 0.66). Comparative analysis of the 5-HT levels
between hyper and normoserotonemic ASD groups was done
using Mann Whitney U-test.
We have also analyzed the plasma 5-HT level in 93 ASD
(age: 5.63 ± 0.37 years; mean ± SEM) and 40 control (age:
5.85 ± 0.54 years) children. The plasma 5-HT level did not show
any differences between the two groups. Since we found that it is
not altered in the cases and controls, we did not do any further
analysis with it.
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RESULTS
Analysis of the CARS Score and Its
Comparison Between Male and Female
ASD Probands
Distribution of cumulative CARS score and score for each of the
15 behavioral items was estimated for male, female and total ASD
probands. The mean value of the scores and their ranges are listed
in Supplementary Table S1. Comparison of the mean CARS
score values between male and female probands revealed higher
score in females than in the males (Table 1). While analyzing the
15 behavioral phenotypes, the mean scores for object use and
nonverbal communication were significantly higher in female
ASD probands than in the males as given in Table 1.
According to CARS, the cut off score of the symptoms for
autism is 30.0. As mentioned in the Methods, the probands
were categorized as mild/moderate or severe based on the CARS
score. In the present study total 215 subjects were enrolled which
included 180 males and 35 females in a ratio 5:1 (Table 2).
Among the 215, 141 were categorized as mild to moderate (66%)
and 74 as severe (34%) cases depending on the CARS score.

TABLE 1 | Mean value of the cumulative CARS score and the score of each
behavioral item for ASD Probands.
ASD probands

N

Mean score ± SEM

Range of
the score

Total

215

34.92 ± 0.27

29.0–50.0

Males

180

34.67 ± 0.28

29.0–43.5

Females

35

36.33 ± 0.73

30.0–50.0

Total

215

2.53 ± 0.03

1.5–3.5

Males

180

2.50 ± 0.04

1.5–3.5

Females

35

2.70 ± 0.07

1.5–3.0

t-test
p-value

CARS
0.050

Object use
0.029

Nonverbal communication

3

Total

215

2.39 ± 0.03

1.5–4.0

Males

180

2.37 ± 0.03

1.5–4.0

Females

35

2.54 ± 0.08

2.0–4.0

0.037
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Male ASD probands (180) consisted of 68 and 32% mild to
moderate and severe cases respectively. The percentage of mild
to moderately and severely affected cases in females were 51 and
49%, respectively. As shown in Table 2 the percentage of severely
affected cases were comparatively higher in females than in males.

Analysis of Platelet and Plasma 5-HT
Levels
Analysis of platelet 5-HT level in ASD cases and age-matched
controls of same ethnic origin were performed. The cut off
value for platelet hyperserotonemia was 14.7 nmol/109 platelets,
which was calculated as 95th percentile of the 5-HT value
in the controls. In 21 out of 104 ASD cases (20.2%) and
2 out of 26 age-matched controls (7.7%), the observed 5HT content in the platelets was above this threshold value.
Cut off value of hyperserotonemia in male subjects was
comparatively less (9.04 nmol/109 platelets). In male participants
33 ASD cases (37.93%) and 1 control child (6.77%) belonged
to hyperserotonemic category. On the other hand, females
exhibited a higher threshold value of 16.5 nmol/109 platelets
for hyperserotonemia and it was present only in 4 ASD cases
(23.53%) and 1 control child (9.09%). Comparative analysis
of the 5-HT levels using Mann Whitney U-test in hyper and
normoserotonemic ASD groups revealed significant increase in
platelet 5-HT in hyperserotonemic male, female and control
children in comparison to the normoserotonemic groups as
shown in Figure 1.

FIGURE 2 | Comparison of platelet 5-HT levels (A), platelet (B) and plasma
5-HIAA (C) levels between ASD cases and controls. Median values of platelet
5-HT, platelet and plasma 5-HIAA levels in total (F + M), male (M) and female
(F) were compared with their respective controls using Mann-Whitney U (M-W)
test. Y -axis of the box-plot diagram shows median 5-HT and 5-HIAA values.
Number of subjects for each group is indicated in the bars. ∗ indicates p-value
to be ≤ 0.05, ∗∗∗ indicates p-value to be ≤ 0.005. Power of this analysis was
calculated assuming equal sample size for cases and controls and the power
of each analysis is as follows: (A) F + M: 51%, M: 84%, F: 69%; (B) F + M:
47%, M: 97%, F: 43%; (C) F + M: 73%, M: 50%, F: 76%. The respective
p-values have been taken as the value for α.

TABLE 2 | Percentage distribution of ASD cases based on severity.
ASD cases

Number (n)

Percentage of mild to
moderate cases (n)

Percentage of
severe cases (n)

Total

215

66% (141)

34% (74)

Males

180

68% (123)

32% (57)

Females

35

51% (18)

49% (17)

As shown in Figure 2A, the platelet 5-HT levels in ASD
cases were 2.5-fold higher than in the controls [controls (N26): 4.63 ± 1.08 nmol/109 platelets; cases (N-104): 10.08 ± 1.42
nmol/109 platelets; M–W test U = 808, p = 0.002]. It was
further increased to approximately 5-fold in male ASD probands
as compared to controls [male controls (N-15): 2.40 ± 0.82
nmol/109 platelets; male ASD cases (N-87): 10.20 ± 1.64
nmol/109 platelets; M–W test U = 215, p = < 0.001]. On
the contrary, in females no significant differences in platelet 5HT levels were observed between cases and controls as shown
in Figure 2A [female controls (N-11): 7.66 ± 1.99 nmol/109
platelets; female ASD cases (N-17): 9.45 ± 2.35 nmol/109
platelets; M–W test U = 91, p = 0.925]. As mentioned in the
Methods section, no differences were observed in the plasma
level of 5-HT (ASD cases: 0.09 ± 0.03 nmol/ml plasma; Young
controls: 0.08 ± 0.03 nmol/ml plasma; M–W test: U = 16.5,
P = 0.35) between 93 ASD cases and 40 controls.

FIGURE 1 | Comparison of platelet 5-HT level in normo- and
hyperserotonemic total, male and female ASD probands. The comparative
analysis was performed using Mann-Whitney U (M-W) test. The number of
ASD participants in each study group is depicted inside the bar graphs. ∗∗∗
indicates p-value to be ≤ 0.005. The power for analysis has been performed
assuming equal sample sizes for each ASD group as 52, 44, and 9 for the
total (M + F), male (M) and female (F) subjects, respectively. Accordingly, all the
three analyses had 100% power.
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Analysis of Plasma and Platelet Levels of
5-HIAA
When plasma 5-HIAA level was compared between total ASD
cases and controls, the differences in levels were statistically
insignificant [controls (N-17): 0.23 ± 0.05 nmol/ml; cases (N-73):
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difference in the median values were not statistically significant
[female controls (N-7): 0.90 ± 0.32 nmol/109 platelets; female
cases (N-14): 0.63 ± 0.29 nmol/109 platelets; M–W test U = 38,
p = 0.415] as shown in Figure 2B.

Gender Specific Changes in 5-HT and
5-HIAA Levels in ASD Cases and
Controls
Interestingly, platelet 5-HT, 5-HIAA and plasma 5-HIAA
levels in typically developing children showed genderspecific differences among males and females. As shown in
Figures 3A–C, all these parameters were higher in the female
controls than in male controls. But statistically significant change
was not observed in these levels between female and male ASD
probands (Figures 3A–C).

Correlation of CARS Scores of ASD
Probands With Platelet 5-HT Levels
Correlation between total CARS score and platelet 5-HT levels
in ASD remained insignificant. However, the score for the level
and consistency of intellectual response trait indicated a negative
correlation with platelet 5-HT levels in total (rs : −0.24, p = 0.015)
and male cases (rs : −0.29, p = 0.005) as shown in Table 3. None of
the other behavioral attributes showed any significant difference.

Correlation of CARS Scores of ASD
Probands With Plasma and Platelet
Levels of 5-HIAA

FIGURE 3 | Comparison of platelet 5-HT, plasma and platelet 5-HIAA levels
between males and females of ASD cases and controls. The comparative
analysis was done using Mann-Whitney U (M-W) test. Panel A represents
comparison of platelet 5-HT, Panel B represents comparison of plasma
5-HIAA, and panel C represents comparison of platelet 5-HIAA. M and F
represent male and female participants, respectively. Left and right bars
denote comparison among controls and cases. The numbers inside the bars
depicts the number of samples in each group. ∗ indicates p-value to be
≤ 0.05, ∗∗ indicates p-value to be ≤ 0.009. Power of the analysis is calculated
as: for (A) controls: 67%, ASD: 10%; (B) Controls: 67%, ASD: 46%;
(C) Controls: 76%, ASD: 66%

Even though the total CARS score failed to show any correlation
with both platelet and plasma 5HIAA, the score for adaptation
to change was positively correlated with platelet 5-HT level
in total ASD cases (rs : 0.24, p = 0.040), which was basically
contributed by the male probands (rs : 0.28, p = 0.033). Similar
positive correlation was observed in female ASD cases for fear or
nervousness (rs : 0.58, p = 0.028) as shown in Table 3.

Correlation of Platelet 5-HT, Plasma and
Platelet 5-HIAA Levels With Age of the
Probands

0.14 ± 0.02 nmol/ml; M–W Test U = 474, p = 0.126] as shown
in Figure 2C. Further analysis based on the sex of the study
subjects demonstrated more than 3.5-fold decrease in plasma
5-HIAA levels in the female ASD cases in comparison to agematched respective controls [cases (N-14): 0.11 ± 0.05 nmol/ml
plasma; controls (N-7): 0.39 ± 0.08 nmol/ml plasma, M–W test
U = 12, p = 0.006]. However, no such differences were observed
for the male subjects [male controls (N-10): 0.13 ± 0.05 nmol/ml;
male cases (N-59): 0.15 ± 0.02 nmol/ml; M–W test U = 266.5,
p = 0.627] as depicted in Figure 2C.
Platelet 5-HIAA level also did not show any statistically
significant differences between total ASD cases and controls as
shown in Figure 2B [controls (N-17): 0.44 ± 0.17 nmol/109
platelets; cases (N-73): 0.55 ± 0.10 nmol/109 platelets; M–W
test U = 551, p = 0.455]. Interestingly, the platelet 5-HIAA level
showed approximately 4.5-fold increase in the male ASD cases as
compared to the controls [controls (N-10): 0.12 ± 0.08 nmol/109
platelets; cases (N-59): 0.53 ± 0.10 nmol/109 platelets; M–W test
U = 180, p = 0.040]. However, in the case of female subjects, the
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Platelet 5-HT and platelet 5-HIAA did not show any correlation
with age of the probands for both ASD cases and controls.
However, a significant negative correlation was observed between
plasma 5-HIAA and age of the female ASD probands (rs : −0.58,
p = 0.028) with no effect in any of the controls (rs : −0.74,
p = 0.333).

Correlation of the CARS Scores With Age
of the Probands
Overall CARS score did not show any correlation with age of
the probands (Table 3). On the contrary, few specific behavioral
attributes such as imitation (rs : −0.15, p = 0.044), listening
response (rs : −0.15, p = 0.042) and nonverbal communication
(rs : −0.23, p = 0.002) showed significant negative correlation
with the age of the probands for total subjects. This effect was
mainly contributed by male ASD probands (imitation - rs : −0.18,
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p = 0.028, listening response - rs : −0.21, p = 0.009, nonverbal
communication - rs : −0.22, p = 0.007). However, in the female
ASD cases none of these traits showed significant correlation.

TABLE 3 | Correlation analysis of CARS scores of ASD traits with platelet levels of
5-HT, 5-HIAA and age of the probands.
Behavioral
phenotypes

Relating to
People

Emotional
Response

Imitation

Body Use

Object Use

Adaptation to
Change

Listening
Response

Taste, Smell,
Touch

Visual Response

Fear or
Nervousness

Verbal
Communication

Activity Level

Nonverbal
Communication

Level and
Consistency of
Intellectual
Response
General
Impression

Overall CARS
score

ASD
subjects

Correlation
with platelet
5-HT
rs , p-value

rs , p-value

rs , p-value

Total

0.00, 0.997

0.07, 0.536

−0.05, 0.473

Male

0.02, 0.858

0.07, 0.598

−0.08, 0.354

Female

−0.04, 0.876

0.00, 1.00

0.09, 0.651

Total

−0.04, 0.720

0.04, 0.681

−0.08, 0.290

Correlation
with platelet
5-HIAA

Correlation
with age of
the proband

Male

−0.05, 0.660

0.04, 0.763

−0.05, 0.556

Female

−0.01, 0.974

−0.02, 0.952

−0.27, 0.175

Total

−0.09, 0.324

−0.03, 0.777

−0.15, 0.044

Male

−0.12, 0.282

−0.05, 0.708

−0.18, 0.028

Female

0.06, 0.824

0.04, 0.868

0.04, 0.840

Total

−0.07, 0.472

−0.11, 0.358

0.12, 0.108

Male

−0.09, 0.415

−0.12, 0.374

0.08, 0.337

Female

−0.00, 0.981

−0.16, 0.573

0.27, 0.169

Total

−0.03, 0.749

0.10, 0.381

−0.07, 0.366

Male

−0.00, 0.991

0.19, 0.141

−0.08, 0.353

Female

−0.13, 0.618

−0.27, 0.340

−0.06, 0.750

Total

0.07, 0.496

0.24, 0.040

0.07, 0.300

Male

0.11, 0.302

0.28, 0.033

0.09, 0.227

Female

−0.03, 0.906

0.02, 0.952

0.06, 0.752

Total

0.01, 0.935

0.04, 0.706

−0.15, 0.042
−0.21, 0.009

Male

0.04, 0.699

0.08, 0.538

Female

−0.07, 0.773

−0.14, 0.615

0.09, 0.622

Total

−0.05, 0.635

−0.07, 0.573

−0.12, 0.108

Male

−0.04, 0.704

−0.01, 0.954

−0.12, 0.141

Female

−0.00, 0.989

−0.38, 0.178

−0.18, 0.359

Total

0.05, 0.590

0.06, 0.613

−0.06, 0.440

Male

0.15, 0.169

0.02, 0.895

−0.05, 0.523

Female

−0.24, 0.351

0.23, 0.407

−0.06, 0.752

Total

0.05, 0.590

0.18, 0.118

−0.02, 0.751

Male

0.07, 0.515

0.08, 0.540

0.00, 0.988

Female

0.04, 0.869

0.58, 0.028

−0.16, 0.415

Total

−0.12, 0.245

0.01, 0.944

−0.04, 0.595

Male

−0.12, 0.280

−0.01, 0.969

−0.05, 0.528

Female

−0.03, 0.906

−0.01, 0.964

−0.00, 0.987

Total

−0.05, 0.618

−0.07, 0.575

−0.05, 0.510

Male

−0.02, 0.868

−0.06, 0.640

−0.05, 0.531

Female

−0.09, 0.751

−0.08, 0.785

0.04, 0.823

Total

−0.04, 0.671

0.20, 0.087

−0.23, 0.002

Male

−0.09, 0.390

0.15, 0.251

−0.22, 0.007

Female

0.20, 0.431

0.29, 0.293

−0.21, 0.276

Total

−0.24, 0.015

−0.13, 0.265

0.04, 0.587

Male

−0.29, 0.005

−0.22, 0.092

0.06, 0.438

Female

0.08, 0.744

0.17, 0.552

−0.17, 0.383

Total

−0.18, 0.067

−0.01, 0.927

−0.04, 0.635

Male

−0.19, 0.069

−0.02, 0.897

−0.04, 0.603

Female

−0.07, 0.795

−0.15, 0.583

−0.06, 0.750

Total

−0.12, 0.239

0.02, 0.862

−0.13, 0.072

Male

0.10, 0.349

0.01, 0.923

−0.14, 0.077

Female

−0.11, 0.680

0.05, 0.856

−0.12, 0.542
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Correlation of Plasma 5-HIAA and
Platelet 5-HIAA Levels With Platelet 5-HT
Levels
Surprisingly, neither plasma nor platelet 5-HIAA levels showed
any significant correlation with platelet 5-HT levels in total,
male or female subjects. Absence of correlation was also
observed between plasma and platelet 5-HIAA levels for the
studied subjects.

DISCUSSION
Present study highlights the importance of serotonergic system
in the gender-specific phenotypic expression, symptom threshold
and male prevalence of ASD. The very first observation of
elevated levels of the neurotransmitter, 5-HT in the whole blood
of ASD children has pioneered the research on neurochemical
basis of autism (Schain and Freedman, 1961). Many focused
research by independent researchers that followed this, has led
to the identification of platelet hyperserotonemia as the first
peripheral biomarker of ASD, which is seen only in a subset of
affected persons (Anderson et al., 1990). Clinical manifestation
of ASD is heterogeneous and it is presumed that alterations in
serotonergic system have an impact on behavioral symptoms.
Outcome of the present study confirms the earlier findings of
platelet hyperserotonemia as an endophenotype of ASD, which
we observed only in males. This is accompanied by an increase
in platelet 5-HIAA levels in the male probands. On the contrary
the 5-HIAA level in the plasma of female cases was low in
comparison to the controls, but this trend was not observed
in the male ASD participants. Moreover, behavioral symptoms
were found to be more severe in the females than males and the
distribution of symptom severity based on CARS showed that
proportion of mild-moderate to severe cases (2.1:1) was higher
in males, whereas it is reduced to 1:1 in ASD females. Of the
various behavioral phenotypes mentioned in CARS, the scores for
object use and nonverbal communication deficits were higher in
females than in male ASDs. When correlating these parameters
with various phenotypes, it was observed that the platelet 5-HT
content of the male ASD probands was inversely correlated to
the score for intellectual ability and consistency. Plasma level of
5-HIAA was directly proportional to the score for adaptation to
change in the male ASD probands. Our study indicates that the
phenotypic score for imitation, listening response and nonverbal
communication decreased with age in male ASD probands. One
pertinent observation of this study is the presence of high level
of 5-HT and 5-HIAA in the female controls, which implies
that gender-bias exists in the distribution of these parameters
normally. All these findings for the first time reveal that there is
a differential impact of 5-HT and 5-HIAA on ASD phenotypes,
which is different in the male and female probands. However, the
results should be dealt with caution due to the limited cohort of
control subjects when stratified by sex.
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differences in ASD susceptibility as melatonin is a known
inhibitor of the estrogen receptor-alpha (Pagan et al., 2014).
Second notable reason could be increased oxidative stress
and immune-inflammatory activity in ASD, which can drive
tryptophan down the kynurenine pathway, linking to data
indicating a role for increased quinolinic acid in ASD (Lim et al.,
2016). This could contribute to perhaps transient alterations in
serotonin e.g., an increased in gut permeability, common in
ASD, would drive oxidative stress/cytokines/LPS that may take
tryptophan away from serotonin synthesis thus affecting the
serotonin level. Thirdly various reports are there which indicates
the effect of estrogen in influencing the behavioral phenotype in a
sexual dimorphic fashion as estrogen has opposite effects in males
and females due to differences in their brain organization (Gillies
and McArthur, 2010). There is also burgeoning evidence that
serotonergic function is modulated by estrogen which ultimately
regulates a variety of behaviors such as mood and cognition
(Amin et al., 2005). All these reasons clearly put forth the
probable background for the sex specific enhancement of platelet
hyperserotonemia and its associated downstream behavioral
abnormalities which are observed in ASD.
Even though platelet 5-HT level is increased in the probands,
there is lack of correlation with the severity of overall phenotypic
expression based on CARS scoring. However, significant negative
correlation of platelet 5-HT level was observed with the score of
level and consistency of intellectual response in male participants.
It suggests that probands with platelet hyperserotonemia has
less problem in their intellectual level and cognitive stability
(Salgueiro et al., 2012). In many cases the intellectual ability of
ASD probands are usually above average and Crespi (2016) in a
recent review suggested autism as a disorder of high intelligence.
A previous report by Cook et al. (1988) suggested that vocabulary
score in normal participants showed negative correlation with
whole blood 5-HT (Cook et al., 1988). In a recent paper it
has been reviewed that serotonergic system plays a role in
cognition, which is modulated by serotonergic receptors (Švob
Štrac et al., 2016). Hyperserotonemic condition in platelets and
in presynaptic region may be a compensatory mechanism to
maintain its level in circulation or in the synapse, where they
exert their activity.
Our findings also revealed gender-specific differences as there
is 3-fold increase in platelet 5-HT in the females as compared
to male controls under normal conditions. The 5-HT level may
increase because of a lift in exposure and reuptake of the free
circulating 5-HT to the platelet and/or the decreased catabolism
of the neurotransmitter in the system. In this study, there is an
increased level of its metabolite, 5-HIAA in the platelets of male
probands, which indicates abnormalities in 5-HT degradation
and clearance of 5-HIAA in the ASD cases. System is fine-tuned
to the increased 5-HT level by increasing its degradation. On
the other hand, females normally have high basal 5-HT level,
which is not different in the affected females also. Females show
decreased catabolism of 5-HT as is evident from the low 5HIAA level in the plasma. However, the 5-HIAA levels are high
in females in comparison to male controls. Analysis of the two
situations reveals that the increased metabolism of 5-HT in ASD
females is to compensate for the elevation of 5-HT level in them.
Our previous genetic reports reveal association MAO genes with

Despite high male prevalence of the disorder, most of them
exhibited low level of phenotypic expression. On the other hand,
proportion of females that displayed severe phenotypes was
high. It implies that in the females the threshold for phenotypic
expressions is high so that it is diagnosed with the existing
tools only when they exhibit higher level of disability. Extreme
male brain hypothesis states that during embryonic stage the
affected male subjects are probably exposed to high levels of
fetal testosterones while in the uterus, which probably explains
the increased prevalence of ASD among them (Baron-Cohen,
2002). Another lead in this direction led to the concept of
female protective model (Robinson et al., 2013). A previous
study suggested that the clinical manifestation of the disorder in
females require a higher mutational burden (Jacquemont et al.,
2014). From these studies it has been revealed that when ASD
phenotype manifests in females it turns out to be more severe.
Our present study revealed that females exhibited high CARS
scores, which was mainly due to the high scores for object use and
nonverbal communication. Happe and his group suggested that
females need to have higher degree of behavioral or intellectual
disabilities to get diagnosed with the condition (Dworzynski et al.,
2012). A later study by Frazier et al. suggested that girls with
ASD diagnosis have low IQ and extreme behavioral problems
and under such conditions those girls with reduced phenotypic
expression are missed out during diagnosis (Frazier et al., 2014).
As shown in the Supplementary Table S1, the mean score for
level and consistency of intellectual response is comparatively
higher in the female probands even though it is not statistically
significant, suggesting that females with ASD have relatively low
intellectual ability.
Social behaviors are mainly regulated by the neurotransmitter,
5-HT. As it has been observed, platelet 5-HT level is elevated in
ASD probands, especially in males. Platelet hyperserotonemia is
a consistent finding in a subset of ASD individuals (Anderson
et al., 2002; Hranilovic et al., 2008). Our current study also
replicated hyperserotonemia in more than 20% of the ASD cases.
Differences in platelet 5-HT level between hyperserotonemic and
normoserotonemic probands in both male and female probands
are also significant. When compared between males and females,
5-HT and 5-HIAA levels showed significantly higher level in
female controls than in males. 5-HT levels have been shown to be
sexually dimorphic and there exists a sex specific enhancement of
platelet 5-HT in male ASD cases (Weiss et al., 2005; Chakraborti
et al., 2016). Our present study indicates that 5-HT level of
hyperserotonemia is 1.8-fold high in females in comparison to
male ASDs. Differential expression of the phenotype in males
and females is presumably a functional effect of this altered
5-HT level, acting either through the 5-HT-mediated signal
transduction or through its neurotrophic effect. Evidences also
exist for the sex-specific effect of SSRI in treating depression
(Dalla et al., 2010; Hiroi et al., 2015).
Possible reasons for this sex specific platelet hyperserotonemia
in ASD are many amongst which notable ones are: decrease
in the activation of the melatonergic pathways arising from an
increase in miR-451, miR-375, and miR-7 leading to a decrease
in 14-3-3 and AANAT stability in ASD, thereby coordinating
increased serotonin with decreased melatonin (Pagan et al.,
2017). This altered melatonin hold strong relevance to sex
Frontiers in Neuroscience | www.frontiersin.org
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and plasma 5-HIAA can be due to the immediate clearance of
5-HIAA via urinary excretion.
Age-dependent change in the expression of the social
interaction and communication phenotype is another important
finding of this study. Phenotypic expression of the behaviors
decreased with increasing age of the probands. The finding is
relevant to early intervention programs of ASD for effective
management of the deficits in social communication and aberrant
behavioral phenotypes. Age-specific effect is restricted to male
probands, suggesting gender dependent modulatory effect for age
associated alterations in serotonergic system. A previous study
demonstrated age dependent decrease in overactivity of 5-HT in
healthy children (Dennis et al., 2013).
Current study generates novel and added information
to substantiate differential effect of serotonergic system on
behavioral expression, which is dependent on the age and sex
of a person. The abstract of this study indicates that 5-HT and
5-HIAA are differentially modulated in males and females to
have differential effect on age-dependent changes in behavioral
expression in males and females affected with ASD. Correlation
of male-specific decrease in 5-HT with increased intellectual
disability, male-specific low level of 5-HT and 5-HIAA in
controls, and presence of apparently mild ASD symptoms in
males suggest that males are more vulnerable and need only a low
threshold symptom level to express ASD phenotypes. Probably
it increases the incidence of ASD in males in comparison
to females, where the threshold of symptom level is high. It
may be due to high 5-HT and 5-HIAA level, making the
prevalence in females low.
This study open avenues for further investigation on 5HT homeostasis and platelet hyperserotonemia to contribute to
variable expression and severity of behavioral symptoms of ASD.
Remedial measures to improve behavioral symptoms of ASD are
mostly directed to serotonergic system. Serotonergic functions
are regulated at the genetic level and ASD-specific behaviors
have genetic effect mediated through serotonergic genes (Muller
et al., 2016). Our genetic studies on MAOA (Verma et al., 2014),
MAOB (Chakraborti et al., 2016), VMAT2 (unpublished), and
ENT4 (unpublished) genes supports this concept, and most genes
show gender-bias in association. Multiple etiological factors, to
name a few the genetic, epigenetic, neurological factors and
clinical heterogeneity make ASD highly complex, that needs to
be evaluated through an integrated approach. Gender specific
phenotypic expression of ASD phenotype and high prevalence of
ASD are important areas of research, which need to be evaluated
further. As mentioned in the Methods section, for neurochemical
analysis we excluded the subjects taking medicines, nutritional
supplements and vitamins that could affect levels of 5-HT
and 5-HIAA. This is the main reason behind the low sample
size. Therefore, the major limitation of our study is the low
sample size, especially when the controls are stratified on the
basis of gender.

autism, and that also in a gender specific manner (Verma et al.,
2014; Chakraborti et al., 2016). We have also shown that 5-HT
transporter gene influences ASD (Jaiswal et al., 2015). Therefore,
it is likely that genetic influence of serotonergic system genes
has a regulatory role on the mechanism and maintenance of
serotonergic function and homeostasis, which is differentially
modulated in female and male ASD subjects. It is also apparent
from the results that the mechanism by which 5-HT regulates the
behavioral phenotype is different in boys and girls affected with
ASD, possibly in a heritable manner.
Alterations in the levels of 5-HIAA in the blood and urine
are not consistent in autism (De Grandis et al., 2010; Adamsen
et al., 2014). As platelet serotonergic system in the periphery
is supposed to replicate the CNS scenario, the current findings
on blood 5-HT and 5-HIAA may reproduce the CNS status of
serotonergic profile, however the tryptophan hydroxylases (TPH)
in the CNS is different from that of the periphery. Being a
neurodevelopmental disorder, ASD-specific neurodevelopmental
alterations occur during early fetal stage, during which the TPH
in the periphery is only expressed.
Hyperserotonemic condition in CNS results from an
increased 5-HT uptake and storage in the presynaptic region,
which is likely to reduce the level of synaptic 5-HT for
effective neurotransmission. Few neuroimaging studies in ASD
demonstrate decrease in 5-HT2 receptor binding and reduction
in synaptic signal transduction (Murphy et al., 2006; Goldberg
et al., 2009). Therefore, possibility of modification of behavioral
phenotype through altered serotonergic signaling mechanisms
cannot be ruled out. It has been shown that dietary depletion
of the 5-HT precursor, tryptophan in drug-free adult ASDs
results in worsening of the stereotypic behavior and irritability
(McDougle et al., 1996). The findings that SSRIs ameliorate
certain ASD behavioral symptoms suggests strong correlation
between behavior and 5-HT (Aman et al., 2005; Doyle and
McDougle, 2012). Rodent model of knock-in SERT, Gly56Ala
recapitulates ASD symptoms like hyperserotonemia, and
deficits in social communication as well as repetitive behaviors
(Veenstra-VanderWeele et al., 2012). In a recent review by Muller
et al. (2016) it has been suggested that serotonergic system is
the primary target that can be considered for drug development
strategies in ASD, especially in subjects with hyperserotonemia
as heritable biomarker.
Concomitant with the increase in 5-HIAA in male ASD
probands there is an associated increased score for adaptation to
change. It means that 5-HIAA increases the severity of certain
parameters of social communication phenotype in these children.
On the other hand, female ASD participants showed lower
plasma 5-HIAA level, but their platelet level of 5-HIAA remained
unaltered, which showed positive correlation with the score for
fear and nervousness and results in behavioral inconsistency.
Our findings also indicate lack of correlation between platelet
5-HT levels with either platelet or plasma 5-HIAA levels. The 5HIAA is excreted through urine and increased level of urinary
5-HIAA has been reported in autism (Hanley et al., 1977;
Mulder et al., 2010). Clearance of 5-HIAA through urinary
excretion is probably vital to keep the circulatory level in
equilibrium and for 5-HT homeostasis. Lack of correlation
between serum/platelet 5-HT and 5-HIAA and between platelet
Frontiers in Neuroscience | www.frontiersin.org
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